Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, March 2000, p. 288-292, Vol. 7, No. 2
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Development, Characterization, and Diagnostic
Applications of Monoclonal Antibodies against Bovine
Rotavirus
Yousif
Al-Yousif,
Fahad
Al-Majhdi,
Cindy
Chard-Bergstrom,
Joe
Anderson, and
Sanjay
Kapil*
Department of Diagnostic
Medicine-Pathobiology, College of Veterinary Medicine, Kansas State
University, Manhattan, Kansas 66506
Received 4 October 1999/Returned for modification 13 December
1999/Accepted 14 January 2000
 |
ABSTRACT |
Hybridomas secreting monoclonal antibodies (MAbs) against the
Nebraska calf diarrhea strain of bovine rotavirus (BRV) were characterized. Indirect fluorescent-antibody assay, immunodot assay,
and immunoprecipitation were used to select hybridomas that produced
anti-BRV MAbs. Seven of the MAbs were shown by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and Western blot assay to be
reactive with the BRV outer capsid protein, VP7, which has a molecular
mass of 37.5 kDa. None of the seven MAbs were reactive with canine
rotavirus, bovine coronavirus, or uninfected Madin-Darby bovine kidney
cells. Two clones, 8B4 (immunoglobulin G2a [IgG2a]) and 2B11 (IgG1),
were found suitable for use in an antigen capture enzyme-linked
immunosorbent assay for detecting BRV in bovine fecal samples. Both
were subtype A specific (G6 subtype) but did not react with all
isolates of BRV group A.
 |
INTRODUCTION |
Rotavirus, a member of the
Reoviridae family, is an important cause of gastroenteritis
in young children, calves, monkeys, chickens, pigs, sheep, and horses
(1, 14). It is nonenveloped and has double-shelled capsids
surrounding a genome of 11 double-stranded RNA segments. Seven
serological groups of rotavirus, A to G, have been identified, but only
groups A, B, C, D, and G have been characterized well (15).
Each group can be differentiated by polyacrylamide gel electrophoretic
mobilities (2, 23).
Among the seven serogroups, group A rotavirus has been studied in
greatest detail, and it is the serogroup most commonly found in cattle
worldwide. The virus is composed of a core surrounded by VP6, the major
inner capsid protein. The outer capsid layers of infectious bovine
rotavirus (BRV) particles contain two proteins, VP4 and VP7. The VP4
(P) types are spike protein encoded by RNA segment 4 (19,
21). They constitute important outer capsid proteins with various
functions such as hemagglutinating activity (22) and
neutralization activity (10, 25, 37), and when cleaved by
trypsin into VP5 and VP8, they enhance the infectivity of the virus.
There is evidence that rotavirus VP4 sequences are diverse
(32). Using monoclonal antibodies (MAbs) against VP4, diversity has been shown in the amino acid sequences of epitopes that
are critical for cross-reaction and neutralization of rotaviruses (18, 19, 22, 33). Both VP4 and VP7 are associated with stimulation of serotype-specific antibodies and in vivo protection. Serotypes 1 to 4 of VP7 are glycosylated (6). Proteins other than VP4 and VP7, such as VP6, associated with stimulation of serotype-specific antibodies, may participate in protection against BRV
infection; however, neutralizing antibodies in vitro have been shown to
be specific against VP4 and VP7. Protection against rotavirus infection
appears to rely mainly on stimulation of neutralizing antibodies
against the outer capsid proteins, VP4 and VP7 (27).
Many established protocols and commercial kits are available to detect
rotavirus infection for human diagnostic medical applications including
electron microscopy and enzyme-linked immunosorbent assay (ELISA). The
objective of this study was to develop MAbs against bovine rotavirus
that can detect group A rotavirus antigen in bovine fecal samples by
ELISA and indirect fluorescent-antibody assay (IFA) for diagnostic and
research use.
 |
MATERIALS AND METHODS |
Virus propagation and purification.
The Nebraska calf
diarrhea strain of BRV (serogroup A, serotype G6), obtained from the
National Veterinary Service Laboratory at Ames, Iowa, was passaged six
times in Madin-Darby bovine kidney (MDBK) cells in Dulbecco's modified
Eagle medium containing trypsin (5 µg/ml) and pancreatin (5 µg/ml)
(16). Virus was harvested when 75% of the infected
monolayer showed typical cytopathic effects such as rounding and
detachment of cells. A previously described procedure for virus
purification was followed (17). After three cycles of
freezing and thawing, the cells were scraped, pooled, and centrifuged
at 35,000 × g for 20 min at 4°C in a Sorvall TH641 rotor. The supernatant was passed through a 0.45-µm-pore-size filter,
and then polyethylene glycol 8000 was added at a final concentration of
8% (wt/vol). After incubation overnight at 4°C, the precipitated
virus was centrifuged at 10,800 × g for 20 min at
4°C in a Sorvall TH641 rotor. Pelleted virus was resuspended in a
minimal volume of TNE buffer (100 mM NaCl, 50 mM Tris-HCl [pH 7.5], 1 mM EDTA). Virus was purified on a discontinuous sucrose gradient (10 to
60% [wt/wt]) and then centrifuged at 90,000 × g for
2 h at 4°C in a Sorvall TH641 rotor. The interphase band was
collected, diluted in 1× TNE buffer (pH 7.5), and layered on a 20 to
60% (wt/wt) sucrose gradient for centrifugation at 90,000 × g overnight at 4°C. Fractions were collected in 1-ml volumes
and then centrifuged at 90,000 × g for 2 h. The
purified virus pellet was resuspended in 1× TNE buffer (pH 7.5) for
storage at
20°C, and the protein content was quantitated by the
bicinchoninic acid method (Pierce Chemical Company, Rockford, Ill.).
Production of MAbs.
Four-week-old BALB/c mice were injected
subcutaneously with 60 µg of purified BRV viral proteins mixed with
an equal volume of adjuvant containing TDM plus MPL plus pokeweed
mitogen (Ribi ImmunoChem Research, Inc., Hamilton, Mont.). After three
injections were administered at 2-week intervals, the mice were
sacrificed and their spleen cells were fused with mouse Ag8 myeloma
cells by a standard protocol (7). ELISA, IFA, immunodot
assay, Western blot assay, immunoprecipitation, and
immunohistochemistry (IHC) were used to screen hybridoma supernatants
for reactivity to BRV. The BRV-positive hybridomas were selected and
cloned by limiting dilution. Isotyping of the MAbs was performed using
a commercial kit (Bio-Rad Labs, Richmond, Calif.) according to the
manufacturer's instructions.
Indirect ELISA for hybridoma screening.
Immunolon 1 flat-bottom microtiter plates (Dynex Technologies, Chantilly, Va.) were
coated with 50 ng of purified BRV protein per well and incubated
overnight at 4°C. A blocking solution of 2% casein enzymatic
hydrolysate (Sigma, St. Louis, Mo.) in 0.01 M phosphate-buffered saline
(PBS) (pH 7.0) was added to each well (50 µl), and the plate was
incubated at 37°C for 25 min. Wells were washed five times with PBS
containing 0.05% Tween 20 (PBS-T). Fifty microliters of hybridoma
supernatant was added to each well, and the plate was incubated at
37°C for 25 min. The plate was washed five times with PBS-T, followed
by the addition of 50 µl of secondary goat anti-mouse immunoglobulin
G (IgG) horseradish peroxidase (HRPO)-conjugated antibody (dilution,
1:10,000) to each well. The plate was incubated at 37°C for 25 min
and then washed five times for 5 min each time with PBS-T. For color
development, 50 µl of 2,2'-azinobis(3-ethylbenzthiazoline sulfonic
acid) (ABTS) substrate was added to each well, the plate was incubated
for 15 to 45 min at 37°C, and the absorbance values were read at 405 nm.
IFA test.
BRV-infected (Nebraska calf diarrhea strain) cell
culture slides were fixed in acetone for 10 min at 4°C, air dried for
10 min, and then incubated with 50 to 70 µl of hybridoma supernatant for 30 min at 37°C in a humidified chamber. The slides were rinsed with 0.01 M PBS (pH 7.4) for 10 min, incubated with a 1:50 dilution of
secondary goat anti-mouse IgG fluorescein isothiocyanate-labeled antibody at 37°C for 30 to 60 min. After the slides were washed in
PBS for 10 min, they were mounted with buffered glycerol (pH 7.2),
coverslipped, and then examined with a fluorescence microscope for the
presence of apple-green fluorescence indicating BRV-infected cells.
Immunodot assay.
A biodot apparatus (Bio-Rad Labs) was used
to stabilize the nitrocellulose membrane for application of
BRV-positive and -negative controls. One microgram of purified BRV was
applied per well for each MAb to be tested. Uninfected MDBK cell lysate
(1 µg) was used for the negative control. After air drying for 10 min, the membrane was cut into strips that were placed in
multireservoir trays and blocked with 10% horse serum for 1 h at
4°C with gentle agitation. Each MAb was tested individually against
the BRV-positive and -negative samples by incubating with the
nitrocellulose strips for 1 h on a shaker at 4°C. The membrane
strips were washed with Tris-buffered saline (TBS) five times for 5 min
per wash. A 1:6,000 dilution of horse anti-mouse IgG HRPO-conjugated
antibody was applied to the strips, which were incubated for 1 h
at 4°C. Prior to adding of 4-chloro-1-naphthol peroxidase (4CN)
substrate for color development, the membranes were washed five times
in TBS for 5 min per wash.
Western blot assay.
Proteins from purified BRV were
separated by 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis and transferred to a nitrocellulose membrane by
electroblotting. The membranes were cut into strips that were placed in
a multichannel reservoir, blocked with 10% horse serum in TBS (0.025 M
Tris [pH 7.4], 0.8% NaCl, 0.02% KCl) at 4°C for 1 h, and
then incubated with 1 ml of hybridoma supernatant at 4°C for 1 h. After the membrane strips were washed with TBS five times for 5 min,
secondary horse anti-mouse IgG HRPO-conjugated antibody was applied,
and the strips were incubated for 1 h at 4°C and then washed
five times for a total of 25 min. Antigen-antibody complexes were
detected colorimetrically by adding 4CN substrate. The BRV protein with
which each MAb reacted was identified by molecular mass, which was
determined by calculating the relative migration of the protein
compared to a protein molecular mass marker.
Immunoprecipitation test.
The BRV proteins were
immunoprecipitated overnight at 4°C with gentle rocking by addition
of 1 ml of clarified infected cell lysate to 50 µl of hybridoma
supernatants or a positive, polyclonal control serum from BRV-immunized
mice. The immune complexes were incubated on ice for 2 h with 10 µl of formalin-fixed Staphylococcus aureus (Cowan 1) which
bound to the MAbs. Cells were centrifuged at 4,000 × g
for 10 min and washed three times for 5 min, first with tryptic soy
agar (TSA) containing 1% Triton X-100 and 1% sodium deoxycholic acid,
then with TSA alone, and finally with 10 mM Tris-HCl (pH 7.5)
containing 1 mM EDTA. After centrifugation at 4,000 × g for 10 min, the pellet was resuspended in 20 µl of sample
loading buffer and electrophoresed on a 12% SDS-polyacrylamide gel
electrophoresis gel. The gel was blotted onto a nitrocellulose membrane, and specificity was tested using bovine anti-rotavirus, polyclonal, hyperimmune serum (National Veterinary Service Laboratory) as an antibody probe. The blot was incubated with secondary goat anti-bovine IgG HRPO-conjugated antibody. For chromagen development, 4CN was chosen as the substrate.
IHC.
Formalin-fixed, paraffin-embedded intestinal tissues in
4-µm sections were used. The tissue sections were heat fixed to glass slides at 55°C for 30 min and then deparaffinized in three changes of
Hemo-De (Fisher Scientific, St. Louis, Mo.) xylene substitute for a
total of 15 min, followed by rehydration through graded alcohols (100% > 95% > 80%) to distilled water. Sections were treated with 0.01%
trypsin for 10 min at room temperature, followed by a 5-min distilled
water wash. To quench endogenous peroxidase, 3%
H2O2 was applied to the tissues for 5 min at
room temperature. The slides were rinsed in distilled water for 5 min
and then soaked in PBS-T for 10 min. A protein blocker (PBA; Lipshaw,
Pittsburgh, Pa.) was applied to the sections for 10 min at room
temperature. Excess blocker was removed, and anti-BRV hybridoma
supernatant (dilution, 1:50) was applied to the tissues for a 2-h
incubation at 37°C. After a 10-min wash in PBS-T, the slides were
incubated with a secondary anti-mouse IgG biotinylated antibody (Vector Labs, Burlingame, Calif.) for 30 min at room temperature and then washed with PBS-T for 10 min. Avidin-biotin complex (Vector Labs) was
applied to the tissues, which were then incubated for 30 min at room
temperature, washed in PBS-T, and soaked in distilled water for 5 min.
As a substrate, DAB was applied to the tissues for 10 min. Following a
5-min distilled water wash, the sections were counterstained with
Gill's hematoxylin 1 (Fisher Scientific) for 30 s and placed
under lukewarm running tap water for 5 min. After the tissues were
dehydrated through graded alcohols (80% > 95% > 100%) to xylene,
they were coverslipped with Permount (Fisher Scientific) and examined
by light microscopy for BRV-positive stained cells.
Antigen capture ELISA for BRV antigen detection.
Immunolon 1 flat-bottom microtiter plates (Dynex Technologies) were coated with
12.5 ng of semipurified or concentrated MAb (8B4 or 2B11) per well and
incubated overnight at 4°C. The plates were washed five times with
PBS-T, and residual moisture was tapped onto a paper towel. A 50-µl
aliquot of blocking solution (0.5% glycine in PBS) was added to each
well, and the plate was incubated at 37°C for 25 min and washed five
times with PBS-T. Fifty microliters of a 10% (wt/vol) fecal suspension
in PBS was added to each well, and the plate was incubated at 37°C
for 25 min. The plate was washed five times with PBS-T, and then 50 µl of rabbit anti-rotavirus HRPO-conjugated antibody (dilution,
1:10,000) was added. The plate was incubated at 37°C for 30 min and
then washed five times with PBS-T. For development, 50 µl of ABTS
substrate was added to each well, the plate was incubated for 15 to 45 min at 37°C, and the absorbance value was read at 405 nm.
Rotazyme.
Detectability and specificity of the MAbs in the
antigen capture ELISA were directly compared with the Rotazyme II kit
(Abbott Laboratories, Abbott Park, Ill.). Bovine fecal samples were
tested using the Rotazyme II kit following the manufacturer's
instructions for human fecal samples.
Calculation of specificity and sensitivity.
The following
formulas were used to calculate the specificity and sensitivity of the
antigen capture ELISA compared to the Rotazyme II kit (36):
(i) sensitivity = [TP/(TP + FN)] × 100, where TP is a
true-positive result as determined by the reference assay and FN is a
false-negative result, and (ii) specificity = [TN/(TN + FP)] × 100, where TN is a true-negative result as determined by the
reference assay and FP is a false-positive result.
 |
RESULTS |
Fusion of spleen cells from immunized BALB/c mice with Ag8 myeloma
cells produced 14 anti-BRV hybridoma cell lines, of which seven were
selected by their specific reactivity with purified BRV antigen as
shown by the screening ELISA and by Western blotting (Table
1) under denaturing conditions. All seven
MAbs bound to native antigen, as shown by immunoprecipitation assays,
and six were reactive by the immunodot assay. Only MAbs 2B11 and 10B1 failed to detect SDS-denatured antigen by Western blotting. Three MAbs,
5F8, 5H8, and 9E7, did not detect acetone-fixed, BRV-infected cells by
IFA. Isotyping of the MAbs, following the kit instructions, showed that
all were isotype IgG1, except for 1B12 and 8B4, which were IgG2b and
IgG2a, respectively (Table 1). Most of the MAbs had a kappa light
chain, and two (10B1 and 1B12) had a lambda light chain.
The size of viral protein immunoprecipitated by each of the seven MAbs
was calculated by comparing the relative mobility of the bound protein
to that of the protein molecular mass marker. A calibration curve of
the protein standard was used, and the value of relative mobility of
the protein to which the MAb bound was applied to the curve to find the
anti-log corresponding to the molecular mass of that protein. All seven
MAbs were shown to precipitate with or bind to a 37.5-kDa protein (Fig.
1), which corresponds in molecular mass
to rotavirus VP7.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 1.
Immunoprecipitation of BRV-infected cytoplasmic cell
lysate. MDBK cells were infected with BRV, and infected cytoplasmic
extracts were immunoprecipitated with MAbs. The lysates were
immunoprecipitated with MAbs 2B11 (lane 6), 8B4 (lane 5), 5F9 (lane 4),
and 5H8 (lane 3). Noninfected cell lysate was used as a negative
control (lane 2), and polyclonal serum against BRV was used as a
positive control (lane 1).
|
|
MAbs were used in antigen capture ELISA, and the results were compared
with those obtained with the Rotazyme II kit (Abbott Laboratories).
Clones 2B11 and 8B4 had the ability to detect rotavirus antigen in
fecal samples. Of 20 samples tested, 18 that were positive by the
Rotazyme II kit were also found positive by MAbs 8B4 and 2B11, with 85 and 39% sensitivity, respectively (Table
2). Sensitivity and specificity of the
antigen capture ELISA using each of the two MAbs were evaluated based
on the Rotazyme II kit being the reference method (specificity of both
MAbs was 100%). Cross-reactivity between BRV antibody and bovine
coronavirus, another virus commonly encountered in fecal specimen of
neonatal calves, was not observed. Cross-reactivity was not observed
with canine rotavirus or with uninfected MDBK cells.
 |
DISCUSSION |
The BRV serotypes are defined according to the reactivity of VP7
to specific MAbs (2, 34). Different segments of BRV encode
the VP7 gene (segment 7, 8, or 9, depending on the strain of the virus)
(6). VP7 is the main antigen for neutralizing antibodies and
determining serotypic differences.
Because binding of an antibody to an antigen is dependent on the
recognition of specific amino acid epitopes by the antibody, MAb
technology has facilitated the development of sensitive and specific
tests for the detection of many microbial and viral antigens in
clinical specimens. Several immunological techniques that incorporate the use of MAbs have been described, including ELISA (3, 5, 7, 23,
24, 26, 29, 34), IFA, and fluorescent-antibody assay (8, 28,
30, 31, 33), immunohistochemical staining of fixed tissues
(35), and immunoblot assays (9). The advantages of using dot blot immunoassays to detect viral antigens directly from
tissues, swabs, washings, and body secretions are as follows: (i) large
numbers of specimens can be handled simultaneously; (ii) culture of
virus in cells, eggs, or laboratory animals is not required; and (iii)
immunoassays are sensitive, specific, and rapid to perform. Coating an
ELISA plate with an antigen of interest can result in a change of the
conformational epitope to which the MAb may bind. To solve this
problem, a sandwich ELISA, in which antibodies are coated in a
microtiter plate to anchor the protein of interest and so retain its
native conformation, is an alternative.
Accurate and effective diagnosis of BRV infection is important for
disease prevention. Current methods for diagnosing infection with BRV
are electron microscopic examination of fecal samples, ELISA, and
direct fluorescent-antibody inspection of frozen sections of the small
intestine. Transmission electron microscopy can detect virus only if
large numbers of particles are present (100,000 particles/g of feces),
and it is expensive, requiring an operator, special equipment, and
skilled personnel. Direct immunofluorescence testing of tissues is
rapid, but it is less sensitive than IFA. The latter generally is
considered to be more sensitive than direct immunofluorescence because
of signal amplification of secondary, labeled antibody. ELISA is
sensitive for detecting rotavirus in feces of humans and calves.
Commercial ELISA kits, such as the Rotazyme II kit, are useful for
detecting rotaviruses of several species because all have a common
group-specific antigen. Most available kits are designed primarily for
human diagnostic testing and are not approved for veterinary
application. Therefore, the use of IFA to detect viral antigen in
acetone-fixed tissues is a good alternative to the ELISA, because it is
a specific and rapid aid for the study of viral pathogenesis.
In this study, we have produced and characterized MAbs specific for
bovine rotavirus. Several screening methods were used to identify
BRV-reactive MAbs: immunodot blotting, Western blotting, immunoprecipitation, and ELISA. Differences noted in the reactivity of
each MAb by the various tests could be due to the sensitivity of the
test or to the conformation of the proteins. For example, both
immunoprecipitation and the immunodot assay identify conformational epitopes, whereas Western blotting identifies linear epitopes. Differences in protein conformation can affect reactivity of the antibodies by sequestering or revealing epitopes or weak affinity to
MAbs. Differences in the immunodot assay and the indirect screening ELISA could be due in part to differences in test sensitivity. The
indirect ELISA is less sensitive than the antigen capture ELISA. Our
results show that IFA had a higher sensitivity than indirect ELISA.
Immunoprecipitation allows better detection of native conformational
epitopes by antibodies than does IFA or dot blot assay. None of the
seven MAbs were positive by the IHC test. We believe that the MAbs were
nonreactive by IHC because BRV epitopes were distorted by cross-linking
induced during formalin fixation of the tissues (3).
This is the first report of MAbs produced against VP7 of Nebraska calf
diarrhea strain BRV by using purified viral particles as immunogen.
MAbs produced by using synthetic peptide from VP7 as the immunogen for
MAb production were unable to detect antirotavirus antibodies as tested
by ELISA (12). In another study that used a VP7 peptide-VP6
conjugate as the immunogen, the MAbs produced provided less protection
than those obtained by using BRV as the immunogen (13). The
MAbs described in this study should aid in serotyping for selection of
vaccine candidates and in development of better diagnostic methods for
detection of BRV. Because the outer capsid shell, VP7, is associated
with stimulation of serotype-specific antibodies, these MAbs may work
well for G-typing (G6 serotype) of group A BRV (11, 19).
Both MAb 8B4 and MAb 2B11 were G6 subtype specific, and they may be
good tools for typing of American and European strains of BRV. These
MAbs serve well for diagnosing BRV infection when acetone-fixed slides
are submitted for diagnostic investigation. Further study is needed to
define and compare the major epitopes and to decide which serotypes (of
serotypes G1, G3, and G6) are bound, because each subunit of VP7
induces a different degree of serum neutralization response
(4), and then to develop a multivalent vaccine against BRV
isolates common in the United States.
 |
ACKNOWLEDGMENTS |
We thank Jill Speier for help with IFA and Teresa Yeary and
Frederick W. Oehme for editorial assistance and advice.
This project was supported by funds from the Kansas Agricultural
Experiment Station, the Dean's Fund Research Proposal, NC-62 Regional
USDA funds for enteric diseases of pig and cattle, and the revenue
generated by Kansas State University Veterinary Diagnostic Laboratory, Manhattan.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Diagnostic Medicine-Pathobiology, College of Veterinary Medicine,
Kansas State University, Manhattan, KS 66506-56061. Phone: (785)
532-4457. Fax: (785) 532-4829. E-mail: kapil{at}vet.ksu.edu.
Contribution 00-86-J from the Kansas Agricultural Station, Manhattan.
 |
REFERENCES |
| 1.
|
Athanassious, R.,
G. Marsolias,
R. Assaf,
S. Dea,
J. Descoteaux,
R. Dulude, and C. Montpetit.
1994.
Detection of bovine coronavirus and type A rotavirus in neonatal calf diarrhea and winter dysentery of cattle in Quebec: evaluation of three diagnostic methods.
Can. Vet. J.
35:163-169[Medline].
|
| 2.
|
Birch, C. J.,
R. L. Heath, and I. D. Gust.
1989.
Use of serotype-specific monoclonal antibodies to study the epidemiology of rotavirus infection.
J. Med. Virol.
24:45-53.
|
| 3.
|
Carson, F. L.
1990.
Histotechnology, p. 10-14.
ASCP Press, Chicago, Ill.
|
| 4.
|
Crawford, S. E.,
M. K. Estes,
M. Ciarlet,
C. Barone,
C. M. O'Neal,
J. Chin, and M. E. Conner.
1999.
Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles.
J. Virol.
73:4813-4822[Abstract/Free Full Text].
|
| 5.
|
Czeruy, C. P., and W. Eichhorn.
1989.
Characterization of monoclonal and polyclonal antibodies to bovine enteric coronavirus: establishment of an efficient ELISA for antigen detection in feces.
Vet. Microbiol.
20:111-122[CrossRef][Medline].
|
| 6.
|
Estes, M. K., and J. Cohen.
1989.
Rotavirus gene structure and function.
Microbiol. Rev.
3:410-449.
|
| 7.
|
Goding, J.
1996.
Purification, fragmentation and isotopic labelling of monoclonal antibodies, p. 104-141.
In
J. W. Goding (ed.), Monoclonal antibodies. Principles and practice. Academic Press, San Diego, Calif.
|
| 8.
|
Heckert, R. A.,
L. J. Saif,
K. H. Hoblet, and A. G. Agnes.
1990.
Development of protein A-gold immunoelectron microscopy for detection of bovine coronavirus in calves: comparison with ELISA and direct immunofluorescence of nasal epithelial cells.
Vet. Microbiol.
19:217-231.
|
| 9.
|
Herbrink, P. F.,
J. Van Bussel, and S. O. Warnaar.
1982.
The antigen spot test (AST): highly sensitive assay for the detection of antibodies.
J. Immunol. Methods
48:293-298[CrossRef][Medline].
|
| 10.
|
Hoshino, M.,
M. Ysereno,
K. Midthun,
J. Flores,
A. Z. Kapikian, and R. M. Chanock.
1984.
Independent segregation of two antigenic specificities (VP3 and VP7) involved in neutralization of rotavirus infectivity.
Proc. Natl. Acad. Sci. USA
82:8701-8704.
|
| 11.
|
Hussein, H. A.,
E. Frost,
B. Talbot,
M. Shalaby,
E. Cornaglia, and Y. El-Azhary.
1996.
Comparison of polymerase chain reaction and monoclonal antibodies for G-typing of group A bovine rotavirus directly from fecal material.
Vet. Microbiol.
51:11-17[CrossRef][Medline].
|
| 12.
|
Ijaz, M. K.,
T. O. Alkarmi,
A. W. El-Mekki,
S. H. Galadari,
F. K. Dar, and L. A. Babiuk.
1995.
Priming and induction of anti-rotavirus antibody response by synthetic peptides derived from VP7 and VP4.
Vaccine
13:3312-3318.
|
| 13.
|
Ijaz, M. K.,
S. K. Attah-Poku,
M. J. Redmond,
M. D. Parker,
M. I. Sabara,
P. Frenchick, and L. A. Babiuk.
1991.
Heterotypic passive protection induced by synthetic peptides corresponding to VP7 and VP4 of bovine rotavirus.
J. Virol.
65:3106-3113[Abstract/Free Full Text].
|
| 14.
|
Kapikian, A. Z.,
J. Flores,
Y. Hoshino,
R. I. Glass,
K. Midthun,
M. Gorziglia, and R. M. Chanock.
1986.
Rotavirus: the major etiologic agent in severe infantile diarrhea may be controllable by a `Jennerian' approach to vaccination.
J. Infect. Dis.
153:815-822[Medline].
|
| 15.
|
Kapikian, A. Z.,
Y. Hoshino,
R. M. Chanock, and I. Perez-Schael.
1996.
Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children.
J. Infect. Dis.
174:65-72.
|
| 16.
|
Kapil, S.,
K. L. Richardson,
C. Radi, and C. Chard-Bergstrom.
1996.
Factors affecting isolation and propagation of bovine coronavirus in human rectal tumor-18 cell line.
J. Vet. Diagn. Investig.
8:96-99[Free Full Text].
|
| 17.
|
King, S., and D. A. Brain.
1982.
Bovine coronavirus structural proteins.
J. Virol.
42:700-707[Abstract/Free Full Text].
|
| 18.
|
Kobayashi, N.,
K. Taniguchi, and S. Urasawa.
1990.
Identification of operationally overlapping and independent cross-reactive neutralization region on human rotavirus VP4.
J. Gen. Virol.
71:2615-2623[Abstract/Free Full Text].
|
| 19.
|
Liu, M.,
P. A. Offitt, and M. K. Estes.
1988.
Identification of the simian rotavirus SA11 genome segment 3 product.
Virology
163:26-32[CrossRef][Medline].
|
| 20.
|
Lucchelli, A.,
S. Y. Kang,
M. K. Jayasekera,
A. V. Parwani,
D. H. Zeman, and L. J. Saif.
1994.
A survey of G6 and G10 serotypes of group A bovine rotaviruses from diarrheic beef and dairy calves using monoclonal antibodies in ELISA.
J. Vet. Diagn. Investig.
6:175-181[Abstract/Free Full Text].
|
| 21.
|
Mackow, E. R.,
J. W. Barne,
H. Chan, and H. B. Greenberg.
1989.
The rhesus rotavirus outer capsid protein VP4 functions as a hemagglutinin and is antigenically conserved when expressed by a baculovirus recombinant.
J. Virol.
63:1661-1668[Abstract/Free Full Text].
|
| 22.
|
Mackow, E. R.,
R. D. Shaw,
S. M. Matsui,
M. N. Dang, and H. B. Greenberg.
1988.
The rhesus rotavirus gene encoding protein VP3: location of amino acids involved in homologous and heterologous rotavirus neutralization and identification of a putative fusion region.
Proc. Natl. Acad. Sci. USA
85:645-649[Abstract/Free Full Text].
|
| 23.
|
McNulty, M. S.,
D. Todd,
G. M. Allan,
J. B. McFerran, and J. A. Green.
1984.
Epidemiology of rotavirus infection in broiler chicken: recognition of four serogroups.
Arch. Virol.
81:113-121[CrossRef][Medline].
|
| 24.
|
Noorduyn, L. A.,
M. J. Meddens,
J. Lindeman,
W. C. Van-Dijd, and P. Herbrink.
1989.
Favorable effect of detergent on antigen detection and comparison of enzyme linked detection systems in an ELISA for Chlamydia trachomatis.
J. Immunoassay
10:429-448[Medline].
|
| 25.
|
Offitt, P. A.,
R. D. Shaw, and H. B. Greenberg.
1986.
Passive protection against rotavirus induced diarrhea by monoclonal antibodies to surface protein VP3 and VP7.
J. Virol.
58:700-703[Abstract/Free Full Text].
|
| 26.
|
Rouch, C. F.,
T. J. G. Raybould, and S. D. Acres.
1984.
Monoclonal antibody capture-linked immunosorbent assay for detection bovine enteric cornoavirus.
J. Clin. Microbiol.
19:3883-3893.
|
| 27.
|
Rugger, F. M.,
K. Johnson,
G. Basile,
J. P. Kreihenbuhl, and L. Svensson.
1998.
Anti-rotavirus immunoglobulin A neutralizes virus in vitro after transcystosis through epithelial cells and protects infant mice from diarrhea.
J. Virol.
72:2708-2714[Abstract/Free Full Text].
|
| 28.
|
Saif, L. J.
1990.
Nongroup A rotavirus, p. 73-96.
In
J. Saif, and K. W. Theil (ed.), Viral diarrheas of man and animals. CRC Press, Inc., Boca Raton, Fla.
|
| 29.
|
Schoenthaler, S. L., and S. Kapil.
1998.
Development and application of a bovine coronavirus antigen detection enzyme-linked immunosorbent assay.
Clin. Diagn. Lab. Immunol.
6:130-132[Abstract/Free Full Text].
|
| 30.
|
Snodgrass, D. R.,
A. J. Herring,
I. Campbell,
J. M. Inglis, and F. D. Hargreaves.
1984.
Comparison of atypical rotaviruses from calves, piglets, lambs and man.
J. Gen. Virol.
65:909-914[Abstract/Free Full Text].
|
| 31.
|
Tahir, R. A.,
K. A. Pomeroy, and S. M. Goyal.
1995.
Evaluation of shell vial cell culture technique for the detection of bovine coronavirus.
J. Vet. Diagn. Investig.
7:301-304[Abstract/Free Full Text].
|
| 32.
|
Taniguchi, K.,
T. Urasawa, and S. Urasawa.
1994.
Species specificity and interspecies relatedness on VP4 genotypes demonstrated by VP4 sequence analysis of equine, feline, and canine rotavirus strains.
Virology
200:390-400[CrossRef][Medline].
|
| 33.
|
Taniguchi, K.,
W. L. Maloy,
K. Nishikawa,
K. Y. Green,
Y. Hoshino,
S. Uraswa,
A. Z. Kapikian,
R. M. Chanock, and M. Gorziglia.
1988.
Identification of cross-reactive and serotype 2-specific neutralization epitopes on VP3 of human rotavirus.
J. Virol.
62:2421-2426[Abstract/Free Full Text].
|
| 34.
|
Tsunemitsu, H.,
Z. R. el-Kanawati,
D. R. Smith,
H. H. Reed, and L. J. Saif.
1995.
Isolation of coronavirus antigenically indistinguishable from bovine coronavirus from wild ruminants with diarrhea.
J. Clin. Microbiol.
33:3264-3269[Abstract].
|
| 35.
|
Unicom, L. E.,
B. S. Coulson, and R. F. Bishop.
1989.
Experience with an enzyme immunoassay for serotyping human group A rotaviruses.
J. Clin. Microbiol.
27:586-588[Abstract/Free Full Text].
|
| 36.
|
Vanrompay, D.,
A. Van Nerom,
R. Ducatelle, and F. Haesebrouck.
1994.
Evaluation of five immunoassays for detection of Chlamydia psittaci in cloacal and conjunctival specimens from turkeys.
J. Clin. Microbiol.
32:1470-1474[Abstract/Free Full Text].
|
| 37.
|
Zhang, Z.,
G. A. Andrews,
C. Chard-Bergstrom,
H. C. Minocha, and S. Kapil.
1997.
Application of immunohistochemistry and in situ hybridization of bovine coronavirus in paraffin-embedded formalin-fixed intestine.
J. Clin. Microbiol.
35:2964-2965[Abstract].
|
Clinical and Diagnostic Laboratory Immunology, March 2000, p. 288-292, Vol. 7, No. 2
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Wigdorovitz, A., Mozgovoj, M., Santos, M. J. D., Parreno, V., Gomez, C., Perez-Filgueira, D. M., Trono, K. G., Rios, R. D., Franzone, P. M., Fernandez, F., Carrillo, C., Babiuk, L. A., Escribano, J. M., Borca, M. V.
(2004). Protective lactogenic immunity conferred by an edible peptide vaccine to bovine rotavirus produced in transgenic plants. J. Gen. Virol.
85: 1825-1832
[Abstract]
[Full Text]
-
Al-Yousif, Y., Anderson, J., Chard-Bergstrom, C., Bustamante, A., Muenzenberger, M., Austin, K., Kapil, S.
(2001). Evaluation of a Latex Agglutination Kit (Virogen Rotatest) for Detection of Bovine Rotavirus in Fecal Samples. CVI
8: 496-498
[Abstract]
[Full Text]